Spikevax JN.1 50 micrograms dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine
Spikevax JN.1 is indicated for active immunisation to prevent COVID 19 caused by SARS-CoV-2 in individuals 12 years of age and older.
Spikevax XBB.1.5 0.1 mg/mL dispersion for injection
Spikevax XBB.1.5 50 micrograms dispersion for injection
Spikevax XBB.1.5 50 micrograms dispersion for injection in pre-filled syringe
Spikevax XBB.1.5 is indicated for active immunisation to prevent COVID‑19 caused by SARS-CoV-2 in individuals 12 years of age and older.
Spikevax bivalent Original/Omicron BA.4-5 (50 micrograms/50 micrograms)/mL dispersion for injection
Emergency Use Authorization (EUA) has been granted in Qatar for Spikevax bivalent Original/Omicron BA.4-5 for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID-19.
Spikevax bivalent Original/Omicron BA.1 (50 micrograms/50 micrograms)/mL dispersion for injection
Emergency Use Authorization (EUA) has been granted in Qatar for Spikevax bivalent Original/Omicron BA.1 for active immunisation to prevent COVID‑19 caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID‑19.
Spikevax (Previously COVID-19 Vaccine Moderna)
Emergency Use Authorization has been granted in Qatar for Spikevax (COVID-19 Vaccine Moderna) to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older.
Tools
Contact Moderna
How can we help you?
Report a Side Effect: Adverse Event Intake Portal
Email Us: WeCare@modernatx.com
Call Us: 00800101103 Sunday - Thursday 9:00 AM to 5:00 PM AST (closed holidays)